{"filing":{"accession_number":"0001628280-26-063046","cik":"0001411685","ticker":"VTGN","company_name":"Vistagen Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-22","report_date":"2026-09-22","primary_document":"vtgn-20260922.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026063046/vtgn-20260922.htm"},"events":[{"id":34336,"run_id":31599,"accession_number":"0001628280-26-063046","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Vistagen announced preliminary positive data from the open-label extension of its PALISADE-4 Phase 3 study of fasedienol for social anxiety disorder, demonstrating safety and efficacy improvements over four months. This is a material clinical milestone for a late-stage biopharmaceutical company's lead product candidate, affecting investor assessment of regulatory pathway and commercialization potential. While not a traditional earnings release or M\u0026A event, the clinical data disclosure represents a significant operational/development milestone that would influence a reasonable investor's view of the company's prospects.","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-09-22","form":"8-K","submitted_at":null,"items":[{"id":38033,"accession_number":"0001628280-26-063046","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vistagen announced preliminary positive data from the open-label extension of its PALISADE-4 Phase 3 study of fasedienol for social anxiety disorder, demonstrating safety and efficacy improvements over four months. This is a material clinical milestone for a late-stage biopharmaceutical company's lead product candidate, affecting investor assessment of regulatory pathway and commercialization potential. While not a traditional earnings release or M\u0026A event, the clinical data disclosure represents a significant operational/development milestone that would influence a reasonable investor's view of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:24:10.567732+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38033,"accession_number":"0001628280-26-063046","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vistagen announced preliminary positive data from the open-label extension of its PALISADE-4 Phase 3 study of fasedienol for social anxiety disorder, demonstrating safety and efficacy improvements over four months. This is a material clinical milestone for a late-stage biopharmaceutical company's lead product candidate, affecting investor assessment of regulatory pathway and commercialization potential. While not a traditional earnings release or M\u0026A event, the clinical data disclosure represents a significant operational/development milestone that would influence a reasonable investor's view of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:24:10.567732+00:00","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-09-22"}]}